Nasal Emulgel’s Role in Preventing Coronavirus Infection.

Publication date: Jun 19, 2025

Background/Objectives: Coronaviruses (CoVs) are a large family of respiratory viruses that cause respiratory illnesses ranging from mild colds to severe diseases such as severe acute respiratory syndrome and pandemics. The nasal cavity is a primary site for CoV entry and transmission. The study aimed to prepare a novel mucoadhesive emulgel specifically formulated with simple, safe, and cost-effective excipients to create a barrier on the nasal mucosa that impedes CoV infection. This formulation strategy was specifically designed to enable rapid and straightforward in vivo translation, addressing a critical gap in preventive measures against respiratory viruses. Methods: Three emulgels, containing macadamia oil, Carbopol and different percentages of hydroxypropyl methylcellulose (1, 1. 2 and 1. 5% (w/v), HPMC), were properly prepared and characterized for mucoadhesion, viscosity, and spreadability. The biological activity against SARS-CoV-2 was evaluated in vitro on infected epithelial cells. Results: The emulgel with 1. 2% HPMC demonstrated optimal physicochemical properties (mucoadhesion: 342 +/- 9 mN/cm; viscosity: 1080 +/- 83 cp; spreadability: 7. 27 +/- 0. 06 cm) suitable for nasal application. Importantly, in vitro biological assays demonstrated that this emulgel significantly inhibits SARS-CoV-2 infection in epithelial cells, indicating an effective barrier to viral diffusion. Conclusions: By employing readily available, safe, and inexpensive excipients, this novel mucoadhesive emulgel offers a practical, scalable, and rapidly translatable nasal prophylactic approach to prevent early SARS-CoV-2 infection, addressing a critical unmet need in pandemic preparedness.

Open Access PDF

Concepts Keywords
Coronaviruses anti-SARS-CoV-2
Hydroxypropyl Mucoadhesive emulgel
Inexpensive Nasal formulation
Macadamia Pandemic prevention
Oil

Semantics

Type Source Name
disease IDO role
disease MESH Coronavirus Infection
disease MESH severe acute respiratory syndrome
disease IDO site
disease MESH infection
pathway REACTOME Translation
drug DRUGBANK Macadamia oil
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Coenzyme M
disease IDO cell
disease MESH respiratory infections
disease MESH influenza
disease MESH viral infection
drug DRUGBANK Flunarizine
disease IDO replication
disease MESH common cold
drug DRUGBANK Oxygen
drug DRUGBANK Nitric Oxide
drug DRUGBANK Sesame oil
drug DRUGBANK Mineral oil
drug DRUGBANK Castor oil
drug DRUGBANK Isopropyl myristate
drug DRUGBANK Tocopherol
drug DRUGBANK Vitamin E
drug DRUGBANK Oleic Acid
disease MESH inflammation
disease MESH oxidative stress
disease IDO process
disease MESH physical barrier
pathway KEGG Viral replication
drug DRUGBANK Hypromellose
drug DRUGBANK Carbopol 974P
drug DRUGBANK Water
drug DRUGBANK Phosphate ion
drug DRUGBANK Potassium Chloride
drug DRUGBANK Sus scrofa stomach
drug DRUGBANK Isoxaflutole
drug DRUGBANK Amber
disease IDO assay
drug DRUGBANK Calusterone
disease IDO protein
disease IDO host
disease IDO production
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Ivermectin
drug DRUGBANK Resveratrol
drug DRUGBANK Diphenhydramine
drug DRUGBANK Chlorphenesin
drug DRUGBANK Microcrystalline cellulose
drug DRUGBANK Darunavir
drug DRUGBANK Naproxen
drug DRUGBANK Eugenol
drug DRUGBANK Tioconazole
drug DRUGBANK L-Cysteine
drug DRUGBANK Chlorhexidine
drug DRUGBANK Metoclopramide
drug DRUGBANK Loratadine
drug DRUGBANK Cyanocobalamin

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *